Last reviewed · How we verify

Chronic- PF-06480605 450 mg SC Q4W — Competitive Intelligence Brief

Chronic- PF-06480605 450 mg SC Q4W (chronic-pf-06480605-450-mg-sc-q4w) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: pharmacological class not specified. Area: Immunology.

marketed pharmacological class not specified IL-4 receptor alpha subunit Immunology Live · refreshed every 30 min

Target snapshot

Chronic- PF-06480605 450 mg SC Q4W (chronic-pf-06480605-450-mg-sc-q4w) — Pfizer.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Chronic- PF-06480605 450 mg SC Q4W TARGET chronic-pf-06480605-450-mg-sc-q4w Pfizer marketed pharmacological class not specified IL-4 receptor alpha subunit
Rimegepant/BHV3000 rimegepant-bhv3000 Pfizer marketed pharmacological class not specified calcitonin gene-related peptide receptor (CGRPR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (pharmacological class not specified class)

  1. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chronic- PF-06480605 450 mg SC Q4W — Competitive Intelligence Brief. https://druglandscape.com/ci/chronic-pf-06480605-450-mg-sc-q4w. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: